Pharmacokinetic evaluation of diquafosol tetrasodium for the treatment of Sjögren's syndrome

Bibliography

• The epidemiology of dry eye disease: report of the Epidemiology Subcommittee of the International Dry Eye WorkShop (2007). Ocul Surf 2007;5(2):93-107
   PubMed Web of Science ®Google Scholar
• Lee AJ, Lee J, Saw SM, et al. Prevalence and risk factors associated with dry eye symptoms: a population based study in Indonesia. Br J Ophthalmol 2002;86(12):1347-51
   PubMed Web of Science ®Google Scholar
• Moss SE, Klein R, Klein BE. Incidence of dry eye in an older population. Arch Ophthalmol 2004;122(3):369-73
   PubMed Web of Science ®Google Scholar
• The definition and classification of dry eye disease: report of the Definition and Classification Subcommittee of the International Dry Eye WorkShop (2007). Ocul Surf 2007;5(2):75-92
   PubMed Web of Science ®Google Scholar
• Nakamura H, Kawakami A, Eguchi K. Mechanisms of autoantibody production and the relationship between autoantibodies and the clinical manifestations in Sjogren's syndrome. Transl Res 2006;148(6):281-8
   PubMed Web of Science ®Google Scholar
• Hayashi Y, Arakaki R, Ishimaru N. The role of caspase cascade on the development of primary Sjogren's syndrome. J Med Invest 2003;50(1-2):32-8
   PubMedGoogle Scholar
• Dawson L, Tobin A, Smith P, Gordon T. Antimuscarinic antibodies in Sjogren's syndrome: where are we, and where are we going? Arthritis Rheum 2005;52(10):2984-95
   PubMed Web of Science ®Google Scholar
• Dawson LJ, Stanbury J, Venn N, et al. Antimuscarinic antibodies in primary Sjogren's syndrome reversibly inhibit the mechanism of fluid secretion by human submandibular salivary acinar cells. Arthritis Rheum 2006;54(4):1165-73
   PubMed Web of Science ®Google Scholar
• Van Horn DL, Schutten WH, Hyndiuk RA, Kurz P. Xerophthalmia in vitamin A-deficient rabbits. Clinical and ultrastructural alterations in the cornea. Invest Ophthalmol Vis Sci 1980;19(9):1067-79
   PubMed Web of Science ®Google Scholar
• Al-Ani A, Ramaesh K, Wykes W. Diagnosis of vitamin A deficiency from its ocular manifestations in a British patient. Can J Ophthalmol 2009;44(5):e43
   PubMedGoogle Scholar
• Kastelan S, Lukenda A, Salopek-Rabatic J, et al. Dry eye symptoms and signs in long-term contact lens wearers. Coll Antropol 2013;37(Suppl 1):199-203
   PubMedGoogle Scholar
• Baudouin C, Labbe A, Liang H, et al. Preservatives in eyedrops: the good, the bad and the ugly. Prog Retin Eye Res 2010;29(4):312-34
   PubMed Web of Science ®Google Scholar
• Hom MM, Nguyen AL, Bielory L. Allergic conjunctivitis and dry eye syndrome. Ann Allergy Asthma Immunol 2012;108(3):163-6
   PubMed Web of Science ®Google Scholar
• Pult H, Riede-Pult BH, Purslow C. A comparison of an eyelid-warming device to traditional compress therapy. Optom Vis Sci 2012;89(7):E1035-41
   PubMed Web of Science ®Google Scholar
• Tatlipinar S, Akpek EK. Topical ciclosporin in the treatment of ocular surface disorders. Br J Ophthalmol 2005;89(10):1363-7
   PubMed Web of Science ®Google Scholar
• Pavesio CE, Decory HH. Treatment of ocular inflammatory conditions with loteprednol etabonate. Br J Ophthalmol 2008;92(4):455-9
   PubMed Web of Science ®Google Scholar
• Wan PX, Wang XR, Song YY, et al. [Study on the treatment of dry eye with Loteprednol Etabonate]. Zhonghua Yan Ke Za Zhi 2012;48(2):142-7
   PubMedGoogle Scholar
• Fan DS, Yu CB, Chiu TY, et al. Ocular-hypertensive and anti-inflammatory response to rimexolone therapy in children. Arch Ophthalmol 2003;121(12):1716-21
   PubMed Web of Science ®Google Scholar
• Lagnado R, King AJ, Donald F, Dua HS. A protocol for low contamination risk of autologous serum drops in the management of ocular surface disorders. Br J Ophthalmol 2004;88(4):464-5
   PubMed Web of Science ®Google Scholar
• Bidet M, De Renzis G, Martial S, et al. Extracellular ATP increases [CA(2+)](i) in distal tubule cells. I. Evidence for a P2Y2 purinoceptor. Am J Physiol Renal Physiol 2000;279(1):F92-F101
   PubMed Web of Science ®Google Scholar
• Gallagher CJ, Salter MW. Differential properties of astrocyte calcium waves mediated by P2Y1 and P2Y2 receptors. J Neurosci 2003;23(17):6728-39
   PubMed Web of Science ®Google Scholar
• Sugamoto Y, Hirai K, Tokoro T. P2Y2 receptor elevates intracellular calcium concentration in rabbit eye suprachoroid. J Med Dent Sci 1999;46(2):83-92
   PubMedGoogle Scholar
• Li Y, Kuang K, Yerxa B, et al. Rabbit conjunctival epithelium transports fluid, and P2Y2(2) receptor agonists stimulate Cl(-) and fluid secretion. Am J Physiol Cell Physiol 2001;281(2):C595-602
   PubMed Web of Science ®Google Scholar
• Tauber J, Davitt WF, Bokosky JE, et al. Double-masked, placebo-controlled safety and efficacy trial of diquafosol tetrasodium (INS365) ophthalmic solution for the treatment of dry eye. Cornea 2004;23(8):784-92
   PubMed Web of Science ®Google Scholar
• Picher M, Boucher RC. Biochemical evidence for an ecto alkaline phosphodiesterase I in human airways. Am J Respir Cell Mol Biol 2000;23(2):255-61
   PubMed Web of Science ®Google Scholar
• Cowlen MS, Zhang VZ, Warnock L, et al. Localization of ocular P2Y2 receptor gene expression by in situ hybridization. Exp Eye Res 2003;77(1):77-84
   PubMed Web of Science ®Google Scholar
• Gendaszewska-Darmach E, Kucharska M. Nucleotide receptors as targets in the pharmacological enhancement of dermal wound healing. Purinergic Signal 2011;7(2):193-206
   PubMed Web of Science ®Google Scholar
• Kellerman D, Sall K, Bokosky J, et al. Diquafosol tetrasodium (INS365) ophthalmic solution is not absorbed systemically in patients with dry eyes. Invest Ophthalmol Vis Sci 2003;44(Suppl):abstract 3740
   Google Scholar
• Yerxa BR, Mundasad M, Sylvester RN, et al. Ocular safety of INS365 ophthalmic solution, a P2Y2 agonist, in patients with mild to moderate dry eye disease. Adv Exp Med Biol 2002;506(Pt B):1251-7
   PubMedGoogle Scholar
• Kamiya K, Nakanishi M, Ishii R, et al. Clinical evaluation of the additive effect of diquafosol tetrasodium on sodium hyaluronate monotherapy in patients with dry eye syndrome: a prospective, randomized, multicenter study. Eye (Lond) 2012;26(10):1363-8
   PubMed Web of Science ®Google Scholar
• Takamura E, Tsubota K, Watanabe H, Ohashi Y. A randomised, double-masked comparison study of diquafosol versus sodium hyaluronate ophthalmic solutions in dry eye patients. Br J Ophthalmol 2012;96(10):1310-15
   PubMed Web of Science ®Google Scholar
• Shimmura S, Ono M, Shinozaki K, et al. Sodium hyaluronate eyedrops in the treatment of dry eyes. Br J Ophthalmol 1995;79(11):1007-11
   PubMed Web of Science ®Google Scholar
• Arita R, Suehiro J, Haraguchi T, et al. Topical diquafosol for patients with obstructive meibomian gland dysfunction. Br J Ophthalmol 2013;97(6):725-9
   PubMed Web of Science ®Google Scholar
• Arita R, Itoh K, Maeda S, et al. Proposed diagnostic criteria for obstructive meibomian gland dysfunction. Ophthalmology 2009;116(11):2058-63; e1
   PubMed Web of Science ®Google Scholar
• Kaido M, Uchino M, Kojima T, et al. Effect of diquafosol tetrasodium administration on visual function in short break-up time dry eye. J Ocul Pharmacol Ther 2013;29(6):595-603
   PubMed Web of Science ®Google Scholar
• Dogru M, Nakamura M, Shimazaki J, Tsubota K. Changing trends in the treatment of dry-eye disease. Expert Opin Investig Drugs 2013;22(12):1581-601
   PubMed Web of Science ®Google Scholar
• Ramos-Casals M, Tzioufas AG, Stone JH, et al. Treatment of primary Sjögren syndrome: a systematic review. JAMA 2010;28;304(4):452-60
   PubMed Web of Science ®Google Scholar
• Yokoi N, Kato H, Kinoshita S. Facilitation of tear fluid secretion by 3% diquafosol ophthalmic solution in normal human eyes. Am J Ophthalmol 2014;157(1):85-92
   PubMed Web of Science ®Google Scholar
• Toda I, Ide T, Fukumoto T, et al. Combination therapy with diquafosol tetrasodium and sodium hyaluronate in patients with dry eye after laser in situ keratomileusis. Am J Ophthalmol 2014;157(3):616-22
   PubMed Web of Science ®Google Scholar